Annotation Detail

Information
Associated Genes
MET
Associated Variants
MET AMPLIFICATION ( ENST00000318493.11 )
MET AMPLIFICATION ( ENST00000318493.11 )
Associated Disease
glioblastoma
Source Database
CIViC Evidence
Description
A 62 year old female was diagnosed with glioblastoma (GBM) WHO grade 4. Treatment included radiation, temozolomide and cediranib. MET amplification was found by FISH, and ALK and MET inhibitor crizotinib treatment was started. A 40% reduction in size of contrast enhancing lesion was seen. After 6 months, progressive disease was seen and crizotinib withdrawn. The authors state this is a first report of response to prospective MET targeted therapy in GBM.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1565
Gene URL
https://civic.genome.wustl.edu/links/genes/52
Variant URL
https://civic.genome.wustl.edu/links/variants/270
Rating
3
Evidence Type
Predictive
Disease
Glioblastoma Multiforme
Evidence Direction
Supports
Drug
Crizotinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
22162573
Drugs
Drug NameSensitivitySupported
CrizotinibSensitivitytrue